Hyderabad sources stated that the Hyderabad's Nizam’s Institute of Medical Sciences (NIMS) which was chosen for human clinical trials on COVID-19 vaccine, is all set to start clinical trials of BBV152 COVID Vaccine from July 7. indian Council of Medical Research (ICMR) on saturday granted permission to NIMS to carry out human clinical trials for COVID-19 vaccine. This is India's first indigenous coronavirus vaccine COVAXIN which is being developed by the indian Council of Medical Research (ICMR).
ICMR working in partnership with National Institute of Virology (NIV) in pune and Bharat Biotech international Limited (BBIL) for the launch of this medicine. ICMR making efforts to launch it by august 15 on Independence Day. After ICMR got approval from Drug Controller General of india (DCGI) for clinical trials of COVAXIN, ICMR has granted permission to NIMS to carry out human clinical trials from July 7.
When speaking to the media, Dr Manohar expressed their happiness over ICMR choosing NIMS for human clinical trials of COVAXIN. He said that ICMR had granted permission to NIMS for clinical trials in view of the experience of the hospital and announced that NIMS will start the COVAXIN human clinical trials from July 7. Dr Manohar said that in the clinical trials process, three types of the vaccine will be given to humans under trials at two doses. The vaccine contains 3 micrograms of one type of vaccine and another 6 micrograms of the different vaccine, said the doctor.
